Show Me the Data™—Closing Clinical Gaps in Gastric and Esophageal Cancer: Advancing Targeted Treatment Strategies Across the Care Continuum

Thanks for your interest in this podcast. Please read this important program information before listening.

Episode Description

In this podcast, experts Manish A. Shah, MD, FASCO; Syma Iqbal, MD; and Haeseong Park, MD, MPH; discuss novel combinations of targeted therapy, immunotherapy, and chemotherapy to treat resectable and unresectable gastroesophageal adenocarcinomas.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Analyze the latest evidence for currently available treatments used in the management of gastric, GEJ, and esophageal adenocarcinomas (GEAs)
• Evaluate emerging clinical trial data for targeted treatment strategies across GEAs
• Select appropriate treatment for patients with GEA based on tumor biomarkers and other individual patient, disease, and treatment considerations
• Implement strategies to mitigate and manage the AEs associated with targeted therapy for GEA

Acknowledgment of Educational Grant Support

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

Faculty:

Manish A. Shah, MD, FASCO

Professor of Medicine
Bartlett Family Professor of Gastrointestinal Oncology
Chief, Solid Tumor Oncology
Weill Cornell Medicine
New York, NY

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Amgen, BeOne, Gilead, Jazz Pharmaceuticals; Grant/Research Funding: AstraZeneca, Bristol Myers Squibb, Merck, Oncolys Biopharma

Syma Iqbal, MD

Associate Professor of Clinical Medicine
Medical Director, Inpatient Services, Norris Cancer Hospital
Medical Director for Ambulatory Services/Infusion Center
Associate Cancer Physician in Chief
Keck School of Medicine
University of Southern California
Los Angeles, CA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astellas, AstraZeneca, BeOne, Cardiff Oncology, Exelixis, Merck

Haeseong Park, MD, MPH

Associate Professor of Medicine
Harvard Medical School
Member, Gastrointestinal Cancer Center
Member, Center for Cancer Therapeutic Innovations
Dana-Farber Cancer Institute
Boston, MA

Disclosures: Advisor, Consultant, Speaker, Honoraria Recipient: Astellas, Daiichi Sankyo, Merck; Grant/Research Funding: Alterome, Amgen, Bolt Biotherapeutics, Chugai, D3 Bio, Exelixis, Genentech, Huaota, Idience, Incyte, Mersana, Mirati/Bristol Myers Squibb, Pfizer, StrataPATH, Tizona, Yuhan

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

The staff of Physicians’ Education Resource^®, LLC, have no relevant financial relationships with ineligible companies.

This podcast, including the narration, was developed by PER^® editorial staff based on an online activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool.

To learn more about this topic, including information on investigations of additional therapeutic agents, go to https://www.gotoper.com/smtd26gea-activity.

Release Date

March 13, 2026

Expiration Date

March 13, 2027

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.